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14
Aim
15
This study examines estimation of seasonal influenza vaccine effectiveness (VE) for a cohort 16 of patients attending general practice in Scotland in 2010/11. The study focuses on the 17 variation in estimation of VE for both virological and clinical consultation outcomes and 18 understanding the dependency on date of analysis during the season, methodological 19 approach and the effect of use of a propensity score model. 20
Methods
21
For the clinical outcomes, three methodological approaches were considered; adjusted 22
Poisson multi-level modelling splitting consultations in vaccinated individuals into those 23 before and after vaccination, adjusted cox proportional hazards modelling and finally the 24 screening method. For the virological outcome, the test-negative case-control study design 25 was employed. 26
Results
27
VE was highest for the most specific outcomes of ILI (Poisson end-of-season VE=47% (95% 28 CI: -69%, 83%); Cox VE=34% (95% CI: -64%, 73.2%); Screening VE=52.8% (95% CI: 3.8%, 29 76.8%)) and a virological diagnosis (VE=54% (95% CI: -37%, 85%)). Using the Cox approach, 30 adjusted for propensity score score only gave VE=46.5% (95% CI: -30.4%, 78.0%). 31
Conclusion
32
Our approach illustrated the ability to achieve relatively consistent estimates of seasonal 33 influenza VE using both specific and less specific outcomes. Construction of a propensity 34 score and use for bias adjustment increased the estimate of ILI VE estimated from the Cox 35 model and made estimates more similar to the Poisson approach, which models differences 36 in consultation behaviour of vaccinated individuals more inherently in its structure. VE 37 estimation for the same data was found to vary by methodology which should be noted Laboratory-confirmed endpoints generate the highest estimates of VE with the test negative 53 design [9] commonly used, such as in Pebody et al. [7] , however using a convenience sample 54 may lead to bias in the control group. Cohort designs such as defined in Castilla et al. [10] 55 allow for monitoring of clinical endpoints such as influenza-like illness (ILI) but their 56 observational nature leads to confounding by indication -whether this be presented as the 57 'healthy vaccine effect' where healthy individuals are less likely to have an outcome inflating 58 VE (often observed with death or hospitalisation outcomes), or conversely the 'health 59 seeking behaviour effect' where vaccinated individuals are more likely to consult their 60 general practitioner decreasing VE. The monitoring of clinical endpoints which occur more 61 commonly than ILI, such as acute respiratory illness (ARI) may lead to less reliable estimates 62 due to reduced specificity especially if the incidence of influenza is low compared to other 63 circulating respiratory pathogens. Consistency of the case definition used for such 64 consultation groupings between countries is also required for comparability [2] . 65 66
The statistical methodology adopted for the study depends on the data format, whether it 67 be individual or aggregate, and the study design used. All analysis was conducted using R version 2.14.1 [19] . 167 168
Results
169
Demographics
170
The tested -81 patients and only 8 were positive for H1N1v and 6 positive for Influenza B (Table  259 4). 260
261
Adjusting for the other factors in the model there was no evidence of any effect on swab 262 positivity of age group, risk group, deprivation and gender ( The sample size for the virology is limited and relatively few vaccinated patients were tested 295 with only 8 positive for H1N1v therefore VE is estimated with low precision. This clearly 296 identifies the need for more virological testing. However in these times of financial austerity 297 a pragmatic line has to be walked between the amount of testing that can be planned 298 versus the public health benefit that can be derived from any expansion to the testing 299 undertaken. It is difficult to separately estimate the effects of TIV from the PIV and there is 300 a suggestion that PIV has as much of a protective effect as TIV. This is in contrast with 301 results from the end of season 2010/11 UK case negative study [7] , which has a much larger 302 number of samples and some of the patients in this report contribute to the UK study. This 303 study showed that PIV and TIV both had positive VE estimates in 2010/11 (PIV only: VE=28% 304 (95% CI: -6%, 51%); TIV: VE=55% (95% CI: 31, 71%). There was a significant improvement in 305 VE for those that had TIV compared to PIV but no significant improvement for those 306 vaccinated with both. This does raise an important issue for VE estimation public health -307 how do we account for the effect (either positive or negative) for receipt of a prior seasonal 308 influenza vaccine and just how far back should we go in the vaccination history? The cohort 309 approach adopted here offers the attraction of being able to make adjustment in any 310 estimation of VE for such concerns. 311 312 Methodology 313
There is no consensus on which cohort method should routinely be employed to provide 314 estimated VE or which clinical endpoint should be used. Exploratory studies such as this as 315 pivotal in examining the relative performance of each method when applied to one dataset. 316
Estimates were found to vary dependent on the statistical methodology used but the 317 conclusions reached regarding effectiveness were mainly consistent. A summary of the 318 advantages and disadvantages of methodologies examined is summarised in Table A documents the vaccine supplier, name of product and vaccine type for each manufacturer. Vaccine lot numbers were incompletely recorded in the extract for vaccines used for each patient.
All vaccines used were administered IM into deltoid muscle and in appropriate dose following manufacturer recommendations -vaccines administered were provided with needles already attached to barrel (see individual manufacturer for detail on gauge and needle length). All vaccine administration was in accordance with NHS Scotland recommendations for ensuring the maintenance of the cold chain. None of the influenza vaccines for the 2010/11 season contained thiomersal as an added preservative.
Concomitant vaccine administration into a different anatomical site (usually contralateral arm) for a small minority of individuals cannot be excluded for polysaccharide pneumococcal vaccination but this data was not collected (75% of those over the age of 65 60-70% of those under the age of 65 in an at risk group have previously received polysaccharide vaccine. Each year as each age cohort turns 65 individuals without prior vaccination are offered pneumococcal polysaccharide vaccination. Revaccination with pneumococcal polysaccharide vaccine is restricted to a small number of patients with chronic renal disease every five years. The overall number of patients in any season receiving concomitant pneumococcal polysaccharide vaccination is estimated to be around 1-2% of all influenza cases). 
